ANIP
ANI Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 102 | +1 | 15.27M | $1.21B | +7 | −5 |
| Q1 2026 | 103 | -4 | 30.24M | $1.11B | +4 | −9 |
| Q4 2025 | 108 | 0 | 15.43M | $1.15B | +1 | — |
| Q3 2025 | 20 | +5 | 7.92M | $725.10M | +5 | −1 |
| Q2 2025 | 13 | -1 | 6.82M | $445.05M | — | −1 |
| Q1 2025 | 11 | +3 | 3.19M | $213.52M | +3 | — |
| Q4 2024 | 8 | -2 | 3.16M | $174.48M | — | −2 |
| Q3 2024 | 9 | -3 | 1.88M | $111.88M | — | −3 |
| Q2 2024 | 12 | — | 1.26M | $80.52M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 407.91K | — | $25.98M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 407.91K | — | $25.98M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 368.34K | — | $23.46M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 368.34K | — | $23.46M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 230.08K | — | $14.65M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 156.80K | — | $9.99M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 43.63K | — | $2.78M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 43.63K | — | $2.78M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 17.53K | — | $1.12M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 17.53K | — | $1.12M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 17.53K | — | $1.12M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Arrowstreet Capital ✦ | 9.30K | — | $592,000 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 8.76K | — | $557,837 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 7.31K | — | $465,246 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 5.88K | — | $375,000 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 4.93K | — | $313,879 | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Marshall Wace ✦ | 3.98K | — | $253,383 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 276 holders, 23.08M shares, $1.74B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 500 sh · $37,740
Officer · 3.16K sh · $243,474
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology